GEn1E Lifesciences Inc.
Biotechnology ResearchUnited States11-50 Employees
GEn1E Lifesciences is a clinical-stage, Phase 2 company accelerating 1st-in-class precision therapies for Immunology, Inflammatory and rare diseases with unprecedented efficiencies using AI. We are enrolling patients for Phase 2 study in the US and the differentiated mechanism of action (MOA) of our next generation kinase modulators has been published in JPET (Journal of Pharmacology and Experimental Therapeutics). We are based in Palo Alto, with a laboratory in Mountain View and are advancing 4 products, with the lead compound accelerated from early discovery to Phase 2 in 2.5 years and seed funding. This program has received Fast Track designation from the FDA and has a partnership with BARDA for precision approach using AI-powered endotyping in clinical studies. Using our well-differentiated "Platform-in-a-Mechanism" development model, GEn1E is advancing three additional drugs, with the two oral therapies for Chronic Diseases close to starting Phase 1. The 4th product is for pancreatic cancer. The team has a track record of drug development and AI with the founder and CEO, Dr. Ritu Lal, having 3 FDA approvals in the US and in Japan.
1-888-653-2347 
support@leadiq.com 
